Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Vision System Aids Melanoma Detection

By HospiMedica International staff writers
Posted on 17 Nov 2011
A computer-assisted melanoma diagnostic tool helps the detection of atypical cutaneous pigmented lesions.

The MelaFind melanoma diagnostic tool is a point-of-care (POC) multispectral system with a handheld component that captures the image of a lesion with a dermoscope, through a thin layer of alcohol applied to the skin. More...
Multiple light wavelengths are used to obtain data from images of suspicious pigmented skin lesions; the data are then analyzed against a proprietary database of melanomas and benign lesions stored on a central computer, using sophisticated algorithms. A report is then transmitted to the physician’s office containing a recommendation of whether the lesion should be biopsied.

The MelaFind is designed to be used only when a dermatologist chooses to obtain additional information for a decision to biopsy, and not to confirm a clinical diagnosis of melanoma. It is not intended to be used as a screening tool or in the evaluation of nonpigmented lesions; banal pigmented lesions; lesions considered definite melanomas; or mucosal, subungual, and other lesions at different anatomic sites. The MelaFind was developed by MELA Sciences (Irvington, NY, USA), and has been approved by the US Food and Drug Administration (FDA).

“There is no such thing as 100% certainty in medicine,” said George Elias, MD, a melanoma expert at Georgetown University (Washington DC, USA). “Ultimately it's the responsibility of the dermatologist to use his clinical judgment to make the best decision. This machine is there to help him, not replace him.”

The device was used by dermatologists in a pivotal study of 1,257 patients (mean age 47 years) on 1,632 pigmented skin lesions that had at least one characteristic of melanoma, which were also biopsied. Of the 114 lesions that were positive for melanoma on biopsy, 112 were tagged as positive by MelaFind, representing a sensitivity of 98.3%, compared to a sensitivity of 70% to 80% for dermatologists reported in the literature.

Melanoma is a malignant tumor of melanocytes. They predominantly occur in skin, but are also found in other parts of the body, including the bowel and the eye. Melanoma is less common than other skin cancers, but it is much more dangerous and causes the majority (75%) of deaths related to skin cancer. Treatment includes surgical removal of the tumor, adjuvant treatment, chemotherapy and immunotherapy, or radiation therapy. The chance of a cure is greatest when the tumor is discovered while it is still small and thin, and can be entirely removed surgically.

Related Links:

MELA Sciences
Georgetown University



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.